Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts

Menée in vitro et in vivo, cette étude met en évidence un mécanisme par lequel le nintédanib inhibe le caractère agressif d'un cholangiocarcinome intrahépatique via la suppression des cytokines issues des fibroblastes CAFs activés

Résumé en anglais

Background : Intrahepatic cholangiocarcinoma (ICC) is a malignancy that is challenging to treat. Fibroblasts in ICC tissues have been identified as cancer-associated fibroblasts (CAFs) that promote the malignant behaviour of ICC cells. An antifibrotic drug nintedanib has been reported to suppress activated hepatic stellate cells in liver fibrosis.

Methods : We investigated whether nintedanib could suppress the cancer-promoting effect of CAFs derived from ICC tissues in vitro and in vivo.

Results : CAFs promoted the proliferation and invasion of ICC cells. Nintedanib suppressed activated CAFs expressing